Begliarzade, Sema,
Sufianov, Albert,
Ilyasova, Tatiana,
Shumadalova, Alina,
Sufianov, Rinat,
Beylerli, Ozal,
Yan, Zhongrui (2024) worldwide due to its high incidence and
mortality rates. To address this issue, there is a need for ongoing
Beylerli, Ozal,
Shi, Huaizhang,
Begliarzade, Sema,
Shumadalova, Alina,
Ilyasova, Tatiana,
Sufianov, Albert (2024) number of patients and contributing significantly to cancer-
related mortality. Conventional diagnostic
contributor to global morbidity and
mortality. Conventional pharmacological treatments have been effective
Gaponov, D.P.,
Khafizov, T.N.,
Kochkina, K.V.,
Chernov, I.I.,
Enginoev, S.T.,
Shaposhnikova, E.I. (2022) access group 2 (4,2%) patients developed access-
related complications-acute thrombosis of the common
therapy (ART), and
mortality for 195 countries
and territories from 1980 to 2015.
Methods For countries
Zagidullin, N,
Ruslan, G,
Anton, T,
Paruir, D,
Sergey, D,
Irina, L,
Valentin, P (2022) SERUM BIOMARKERS IN
MORTALITY RISK STRATIFICATION IN PATIENTS, HOSPITALIZED WITH COVID-19 PNEUMONIA
Zhou, Qi,
Zhang, Daming,
Chen, Xin,
Yang, Zhao,
Liu, Zhihui,
Wei, Baixing,
Jin, Mei,
Feng, Kairu,
Guo, Chunmei,
Sun, Junying,
Chen, Sheng,
Zhang, Ruijia,
Piao, Xiai,
Gareev, Ilgiz,
Sun, Zhenying,
Wang, Xiaoxiong,
Li, Lili,
Zhao, Shiguang,
Yang, Guang (2020) . An ICH outcome score combining D-dimer level for evaluating poor functional outcome and
mortalityMotloch, LJ;,
Jirak, P;,
Gareeva, D;,
Davtyan, P;,
Gumerov, R;,
Lakman, I;,
Tataurov, A;,
Zulkarneev, R;,
Kabirov, I;,
Cai, BZ;,
Valeev, B;,
Pavlov, V;,
Kopp, K;,
Hoppe, UC;,
Lichtenauer, M;,
Fiedler, L;,
Pistulli, R;,
Zagidullin, N (2022) -discharge
mortality of patients with COVID-19 pneumonia.
Methods: Serum soluble ST2, VCAM-1, and hs-TnI were